---

🎙️ Detailed Internal Medicine Presentation Script: Viral Hepatitis

---

SLIDE 1 — TITLE SLIDE

"Good morning/afternoon, colleagues. Today I'll be presenting a comprehensive review of viral hepatitis — covering all five hepatotropic viruses, their epidemiology, pathophysiology, clinical features, serological diagnosis, and current evidence-based management. This remains one of the most globally significant liver diseases, affecting hundreds of millions of people worldwide."

---

SLIDE 2 — OVERVIEW & OBJECTIVES

1. Distinguish the five major hepatitis viruses by virology, transmission, and natural history
2. Interpret serological markers for acute vs. chronic infection
3. Apply current treatment guidelines (EASL, AASLD, WHO)
4. Recognize and manage complications: cirrhosis, HCC, fulminant hepatic failure

"By the end of this presentation, you should be able to differentiate the hepatitis viruses clinically and serologically, understand when to initiate antiviral therapy, and recognize life-threatening complications. We'll focus particularly on HBV and HCV, which carry the greatest burden of chronic disease."

---

SLIDE 3 — DEFINITION & TERMINOLOGY

• The term hepatitis is applied to:
  • (1) Diseases caused by hepatotropic viruses (HAV, HBV, HCV, HDV, HEV) — viruses with specific tropism for the liver
  • (2) Patterns of hepatic injury from non-hepatotropic viruses (EBV, CMV, yellow fever), autoimmune reactions, drugs, and toxins
• Acute hepatitis: <6 months duration
• Chronic hepatitis: Persistence of elevated liver enzymes or hepatic inflammation >6 months

"It's important to clarify the terminology from the outset. The word 'hepatitis' is applied to two distinct groups. First, diseases caused by hepatotropic viruses — those with specific tropism for the liver. Second, a pattern of hepatic injury caused by non-hepatotropic viruses like EBV and CMV, or by drugs and toxins. Today we focus exclusively on the hepatotropic viruses."

---

SLIDE 4 — COMPARATIVE OVERVIEW TABLE

"This comparative table is your anchor for the entire presentation. Memorize the key distinctions: HAV and HEV are fecal-oral and do not cause chronic hepatitis in immunocompetent individuals. HCV has the highest chronicity rate at 80–90%. HDV is unique — it absolutely requires HBV to replicate. And HEV carries a devastating 20% mortality in pregnant women."

---

SLIDE 5 — HEPATITIS A VIRUS (HAV)

Virology

• Nonenveloped, positive-strand RNA picornavirus (genus: Hepatovirus)
• Single serotype → effective vaccine coverage

Epidemiology

• Accounts for approximately 25% of acute hepatitis worldwide
• Endemic in countries with poor sanitation and healthcare infrastructure
• In high-income countries: ~2,800 cases/year in the USA (>95% decline since 1995 vaccine)
• Outbreaks: schools, nurseries, food handlers, shellfish consumption (contaminated seawater)

Transmission

• Fecal-oral route — contaminated water and food
• Shed in stool for 2–3 weeks before and 1 week after onset of jaundice
• Bloodborne transmission very rare (transient viremia)

Pathogenesis

• HAV itself is NOT cytopathic
• Hepatocellular injury mediated by cytotoxic CD8+ T cells (cellular immune response)

Natural History

• Self-limited — does not cause chronic hepatitis
• Fulminant hepatitis in ~0.1% of cases
• No carrier state

"Hepatitis A is a self-limited illness. The virus itself is not directly cytopathic — the liver damage is immune-mediated, driven by cytotoxic CD8+ T cells. Since 1995, the HAV vaccine has reduced rates in the United States by more than 95%. Importantly, HAV does not establish a carrier state and does not cause chronic hepatitis."

---

SLIDE 6 — HAV: SEROLOGY & DIAGNOSIS

"The diagnostic key for HAV is IgM anti-HAV, which appears at symptom onset and is your go-to marker for acute infection. IgG anti-HAV follows and confers lifelong immunity. Fecal viral shedding ends as the IgM titer rises — so by the time your patient presents to clinic with jaundice, they are typically no longer contagious."

---

SLIDE 7 — HAV: MANAGEMENT & PREVENTION

• Primarily supportive (hydration, rest, symptom management)
• Avoid hepatotoxic drugs and alcohol
• No specific antiviral therapy
• Hospitalize if signs of fulminant hepatitis: coagulopathy, encephalopathy

• Vaccine (available since 1995): 2-dose series, >95% efficacy
• Post-exposure prophylaxis: HAV vaccine within 2 weeks of exposure; Immune globulin for immunocompromised
• Improved sanitation, hand hygiene

"Management of HAV is supportive. No antiviral exists. Your clinical role is to identify the rare patient who is progressing toward fulminant hepatic failure — screen for encephalopathy, coagulopathy, and rising bilirubin. Prevention is paramount. The HAV vaccine is one of medicine's great success stories."

---

SLIDE 8 — HEPATITIS B VIRUS (HBV)

Virology

• Partially double-stranded DNA virus — Hepadnaviridae family
• Contains: HBsAg (surface), HBcAg (core), HBeAg (e-antigen, marker of replication)
• Encodes a reverse transcriptase — key drug target

Epidemiology

• ~300 million chronic carriers worldwide
• Estimated 820,000 deaths/year from cirrhosis and HCC
• High endemicity: Sub-Saharan Africa, Southeast Asia, Pacific Islands
• Primary route in endemic areas: perinatal (vertical) transmission
• Primary route in low-endemicity: parenteral, sexual

Transmission Routes

1. Perinatal (most important in endemic areas — SE Asia, Africa)
2. Parenteral — IV drug use, needlestick, blood products
3. Sexual contact
4. Horizontal (household contacts in early childhood)

"Hepatitis B is a global pandemic. Over 300 million people live with chronic HBV infection. The route of transmission determines the likelihood of chronicity. Perinatal transmission — the most important perpetuator of the worldwide epidemic — results in a 90% rate of chronic infection because the neonatal immune system cannot clear the virus. In contrast, adult exposure results in only 5–10% chronicity."

---

SLIDE 9 — HBV: VIROLOGY & REPLICATION

Key Viral Proteins:

• HBsAg (Hepatitis B surface antigen): Marker of infection; persists in chronic carriers
• HBcAg (Core antigen): Found only in hepatocytes; not detectable in serum
• HBeAg (e-antigen): Soluble, secreted protein; marker of active viral replication & high infectivity
• HBV DNA: Direct measure of viral load
• Anti-HBs: Antibody to HBsAg → marker of immunity/recovery
• Anti-HBc IgM: Marker of acute infection
• Anti-HBc IgG: Marker of past or chronic infection

Ground-Glass Hepatocytes (Histopathology)

• Characteristic finding in chronic HBV
• Caused by accumulation of HBsAg in the ER
• Appear as finely granular, pale eosinophilic cytoplasm on H&E staining
• Confirmed by immunohistochemistry for HBsAg

"Understanding HBV serology is fundamental to internal medicine. HBsAg is your screening marker. HBeAg and HBV DNA tell you about replication activity. Anti-HBc IgM diagnoses acute infection even in the 'window period' when HBsAg may have cleared but anti-HBs hasn't yet appeared. On biopsy, the pathognomonic finding in chronic HBV is ground-glass hepatocytes — pale, finely granular cytoplasm caused by HBsAg accumulation, confirmed with immunostain."

---

SLIDE 10 — HBV: SEROLOGICAL PATTERNS

"This table is essential for clinical practice. The 'window period' is the diagnostic pitfall — HBsAg has cleared but anti-HBs hasn't appeared yet. Anti-HBc IgM saves you here. Notice that vaccination produces only anti-HBs without anti-HBc — this distinguishes immunity from vaccination versus natural infection."

---

SLIDE 11 — HBV: NATURAL HISTORY & PHASES OF CHRONIC INFECTION

1. Immune Tolerant Phase: High HBV DNA, HBeAg positive, normal ALT, minimal liver inflammation → common in perinatally infected patients
2. Immune Active (Clearance) Phase: HBV DNA high, HBeAg positive, elevated ALT, active necroinflammation
3. Immune Control (Inactive Carrier) Phase: Low HBV DNA, HBeAg negative/anti-HBe positive, normal ALT
4. HBeAg-negative Chronic Hepatitis: HBV DNA elevated (>2000 IU/mL), HBeAg negative (mutant virus), elevated ALT — clinically significant
5. HBsAg Clearance ("functional cure"): HBsAg seroconversion — rare, associated with improved outcomes

• Nonprogressive chronic hepatitis
• Progressive chronic disease → cirrhosis (in ~20% over 20 years)
• Fulminant hepatitis with massive necrosis
• HCC (200× increased risk compared to non-infected)

"The natural history of chronic HBV is dynamic. Patients cycle through these phases, sometimes spontaneously. The clinically dangerous scenarios are the immune active phase and HBeAg-negative chronic hepatitis — both are associated with significant liver injury and risk of progression to cirrhosis and hepatocellular carcinoma."

---

SLIDE 12 — HBV: TREATMENT INDICATIONS & AGENTS

When to Treat (EASL 2017 / AASLD 2018):

• HBV DNA >2,000 IU/mL AND ALT >ULN + moderate necroinflammation or fibrosis
• Compensated or decompensated cirrhosis with detectable HBV DNA
• HBV DNA >20,000 IU/mL with ALT >2× ULN
• HBeAg-positive, high HBV DNA, age >30 years
• Family history of HCC or cirrhosis; extrahepatic manifestations

First-Line Antiviral Agents:

"All major guidelines — EASL, AASLD, APASL, and WHO — converge on tenofovir and entecavir as preferred first-line agents for chronic HBV. They have the highest barrier to resistance. TAF is preferred over TDF in patients with renal impairment or osteoporosis. Pegylated interferon offers the advantage of a finite treatment course and the possibility of immune-mediated HBeAg seroconversion, but cannot be used in decompensated cirrhosis."

---

SLIDE 13 — HEPATITIS C VIRUS (HCV)

Virology

• Enveloped, single-stranded RNA virus — Flaviviridae family
• Genome encodes a single polyprotein → processed into 10 functional proteins:
  • NS3/4A protease: required for polyprotein processing → drug target
  • NS5A: essential for viral assembly → drug target
  • NS5B RNA polymerase: required for replication → drug target
• Low-fidelity RNA polymerase → generates quasispecies → rapid genetic variation
• 7 major genotypes (Gt1–7), multiple subtypes → treatment selection depends on genotype

Epidemiology

• ~58 million people with chronic HCV globally (WHO 2023)
• Accounts for ~1/3 of liver cancer cases in the United States
• Major cause of liver transplantation

Transmission

• Primarily parenteral: IV drug use (IDU) — most common in high-income countries
• Blood transfusion (now near zero with screening)
• Needlestick risk: ~1.8% (vs 0.3% for HIV)
• Perinatal: ~5–6% from HCV-positive mothers
• Sexual: inefficient; higher risk in HIV-coinfected MSM
• One-third of patients have no identifiable risk factor

"Hepatitis C is the great masquerader of hepatology — 85% of acute infections are completely asymptomatic, yet 80 to 90% progress to chronic hepatitis. The virus's genetic variability is remarkable — low-fidelity RNA polymerase creates quasispecies in every patient. This genetic plasticity is why resistance testing matters before treatment. The good news: we now have the tools to cure virtually everyone."

---

SLIDE 14 — HCV: NATURAL HISTORY

• Incubation: 4–26 weeks (mean 9 weeks)
• 85% asymptomatic at the time of acute infection
• HCV RNA detectable in blood within 1–3 weeks of exposure
• Milder acute illness than HBV; severe acute hepatitis rare

• 80–90% of acutely infected individuals develop chronic infection
• Characteristic: episodic ALT elevations separated by periods of near-normal levels
• Cirrhosis in approximately 20% over 20–30 years
• Risk factors for progression: older age, male gender, alcohol use, immunosuppression, HBV/HIV coinfection, insulin resistance/metabolic syndrome, obesity, type 2 diabetes
• Important: Even patients with normal transaminases and detectable HCV RNA require treatment and monitoring

• Cirrhosis → HCC (HCV accounts for ~1/3 of U.S. liver cancer)
• Extrahepatic: cryoglobulinemia, membranoproliferative GN, lymphoma

"The natural history of HCV underscores why universal testing is so important. The acute infection is silent in 85% of patients. They go undiagnosed for decades, developing cirrhosis and HCC without ever knowing they were infected. This is why the CDC now recommends one-time HCV screening for all adults aged 18–79. Critical point: even patients with normal transaminases who have detectable HCV RNA have ongoing liver damage and need treatment."

---

SLIDE 15 — HCV: SEROLOGICAL DIAGNOSIS

"The diagnostic algorithm is sequential: screen with anti-HCV antibody, confirm with HCV RNA. A positive antibody with undetectable RNA means resolved infection — follow with a repeat RNA if recent exposure is suspected. Genotyping is essential before prescribing DAAs, particularly for regimens that are genotype-specific."

---

SLIDE 16 — HCV: TREATMENT — DIRECT-ACTING ANTIVIRALS (DAAs)

Four Classes of DAAs:

Current Preferred Regimens (without cirrhosis):

• SVR rates: >95% with modern DAA regimens
• SVR reduces risk of liver decompensation, HCC, liver-related mortality, and all-cause mortality

Important Safety Consideration:

• Test all patients for HBV before starting DAAs — HBV reactivation has been reported in HBV/HCV co-infected patients during DAA therapy, potentially causing fulminant hepatitis and death

"The DAA revolution has transformed HCV from a feared chronic disease to a curable condition. Modern pan-genotypic regimens like sofosbuvir-velpatasvir achieve cure rates above 95% in 12 weeks — or even 8 weeks with glecaprevir-pibrentasvir in treatment-naïve patients without cirrhosis. NS5A resistance variants matter for genotype 1a and 3 — consider baseline resistance testing. One critical safety point: always screen for HBV co-infection before starting DAAs, as reactivation can be fatal."

---

SLIDE 17 — HEPATITIS D VIRUS (HDV)

Virology

• Defective RNA virus — requires HBV (specifically HBsAg) for its envelope
• Cannot cause infection independently — absolutely requires HBV co-infection
• Small, circular, negative-sense ssRNA genome
• Contains only one protein: HDAg (hepatitis D antigen)

Two Clinical Presentations:

1. Coinfection: HDV + HBV simultaneously
   • Generally self-limited; resolves with HBV clearance
   • Fulminant hepatitis more common than HBV alone
   • Low risk of chronicity
2. Superinfection: HDV in patient with established chronic HBV
   • High risk of severe, rapidly progressive chronic hepatitis
   • Cirrhosis accelerated; develops in 70–80%
   • Highest risk of fulminant hepatitis
   • Higher risk of HCC

Epidemiology

• ~12–15 million co-infected globally
• Endemic in Mediterranean, Middle East, Central Asia, Amazon basin

Diagnosis

• Anti-HDV antibody (IgM for acute; IgG for chronic)
• HDV RNA — quantitative, confirms active replication

Treatment

• Pegylated IFN-α (48 weeks): Only established treatment; response rates poor (~25%)
• Bulevirtide (entry inhibitor): Approved in Europe 2020 — new mechanism, promising early data
• Ultimately: Treat underlying HBV with NAs; prevent new HBV infection (vaccination) → prevents HDV

"Hepatitis D is the most severe form of viral hepatitis. Its unique dependency on HBV means that preventing HBV with vaccination completely eliminates the risk of HDV. Superinfection — HDV in someone already chronically infected with HBV — carries particularly poor outcomes, with cirrhosis developing in up to 80%. Treatment options remain limited, though bulevirtide represents a major advance approved in Europe."

---

SLIDE 18 — HEPATITIS E VIRUS (HEV)

Virology

• Non-enveloped, positive-sense ssRNA virus — Hepeviridae family
• 4 genotypes, 1 serotype
• Gt 1 & 2: Infect humans only → epidemic disease (monsoon season, Asia/India)
• Gt 3 & 4: Zoonotic — infect humans, swine, chickens, cattle, sheep → sporadic disease in farmers

Transmission

• Fecal-oral (contaminated water) — Gt 1 & 2
• Zoonotic (undercooked pork/poultry) — Gt 3 & 4

Clinical Features

• Usually self-limited in immunocompetent individuals
• Pregnant women (3rd trimester): Fulminant hepatic failure — mortality up to 20%
• Also associated with: intrauterine fetal death, preterm delivery, neonatal hepatitis (vertical transmission)
• Chronic HEV: reported in immunosuppressed patients (solid organ transplant recipients, HIV) with Gt 3

Diagnosis

• Anti-HEV IgM: Acute infection
• Anti-HEV IgG: Past exposure / immunity
• HEV RNA (PCR): Confirms active infection, especially in immunosuppressed

Treatment

• Supportive; no proven specific therapy for immunocompetent
• Ribavirin ± pegylated IFN-α in chronic HEV (immunosuppressed)
• Reduce immunosuppression in transplant recipients

Prevention

• Vaccine (HEV 239, Hecolin®): Approved in China (2011)
• Avoid contaminated water; cook meat thoroughly

"Hepatitis E deserves special attention for two reasons. First, its catastrophic impact in pregnancy — acute HEV in the third trimester carries a 20% mortality rate and should be suspected in any pregnant woman returning from or living in endemic areas with acute hepatitis. Second, chronic HEV in immunosuppressed patients — especially solid organ transplant recipients — is an underdiagnosed entity. These patients don't clear the virus, and ribavirin can achieve viral clearance in many."

---

SLIDE 19 — CLINICAL FEATURES OF ACUTE VIRAL HEPATITIS

Prodromal Phase (1–2 weeks before jaundice):

• Fatigue, malaise, anorexia, nausea, vomiting
• Right upper quadrant discomfort
• Low-grade fever
• Arthralgias, myalgias (particularly HBV — immune complex mediated)
• Urticaria/rash (serum sickness-like — HBV)
• Dark urine (bilirubinuria), pale stools (cholestatic phase)

Icteric Phase:

• Jaundice — scleral icterus first, then skin
• Tender hepatomegaly
• Transient splenomegaly in 10–15%
• Pruritis if cholestatic component prominent

Recovery Phase:

• Jaundice fades, appetite returns
• Fatigue may persist weeks to months

Laboratory Findings:

"The clinical presentation of acute viral hepatitis follows a predictable pattern. The prodrome — fatigue, anorexia, nausea — precedes jaundice by 1 to 2 weeks. A critical point for clinical practice: the PT/INR is your best early marker of hepatic synthetic function and your most important prognostic indicator. An albumin below 3 g/dL in newly diagnosed hepatitis should raise suspicion of underlying chronic liver disease, given albumin's long half-life."

---

SLIDE 20 — COMPLICATIONS OF VIRAL HEPATITIS

1. Fulminant Hepatic Failure (Acute Liver Failure)

• Definition: Acute liver failure with coagulopathy and hepatic encephalopathy in a patient without pre-existing liver disease
• Causes among hepatitis viruses: HAV (rare), HBV (especially reactivation), HDV superinfection, HEV (in pregnancy)
• Clinical features: Jaundice, coagulopathy (INR ≥1.5), encephalopathy, cerebral edema → herniation
• Management:
  • ICU admission; treat encephalopathy (lactulose, rifaximin)
  • Correct coagulopathy (FFP, vitamin K)
  • Liver transplantation — Status 1 priority; decision within 24 hours; goal transplant within 48–72 hours
  • MELD score has prognostic value
• Mortality without transplantation: very high (>70% for grade III–IV encephalopathy)

2. Cirrhosis

• End-stage fibrosis following years of chronic hepatic inflammation
• Complications: portal hypertension, ascites, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, spontaneous bacterial peritonitis
• Decompensation: Child-Pugh B/C or MELD ≥15

3. Hepatocellular Carcinoma (HCC)

• HBV: 200× increased risk; can occur even without cirrhosis
• HCV: 1/3 of HCC in the USA; typically occurs on background of cirrhosis
• Surveillance: Ultrasound ± AFP every 6 months in all at-risk patients
• Treatment: Resection, transplantation, ablation, TACE, sorafenib (BCLC staging)

4. Extrahepatic Manifestations (Especially HBV & HCV)

• HBV: Polyarteritis nodosa, membranous GN, serum sickness
• HCV: Mixed cryoglobulinemia, membranoproliferative GN, non-Hodgkin lymphoma, Sjögren-like syndrome, porphyria cutanea tarda

"Complications are where morbidity and mortality concentrate. Fulminant hepatic failure is a medical emergency — decisions about liver transplant listing must be made within 24 hours. The MELD score guides prognosis and prioritization. Cirrhosis should trigger your HCC surveillance protocol — ultrasound every 6 months. Remember that HBV can cause HCC even in the absence of cirrhosis, which is why surveillance applies to all HBsAg-positive patients with high-risk features regardless of fibrosis stage."

---

SLIDE 21 — SPECIAL POPULATIONS

1. HBV in Pregnancy

• Universal HBV screening of all pregnant women is recommended
• Most mother-to-infant transmission occurs at delivery (not in utero)
• Maternal infectivity proportional to viral load; HBeAg-positive mothers have highest transmission rates
• Prevention of vertical transmission:
  • Neonatal HBsAg vaccine + HBIG within 12 hours of birth → 85–95% protection
  • Tenofovir in final trimester if HBV DNA >200,000 IU/mL to further reduce transmission
• Breastfeeding: allowed if infant receives vaccination + HBIG

2. HEV in Pregnancy

• Acute HEV in 3rd trimester → FHF, mortality up to 20%
• Intrauterine fetal death, preterm delivery, neonatal hepatitis (vertical transmission)
• No known therapy prevents vertical transmission
• Avoid travel to endemic areas during monsoon season

3. HIV/HBV or HIV/HCV Coinfection

• Accelerated progression to cirrhosis and HCC
• Use antiretrovirals active against both viruses (tenofovir + emtricitabine in the HIV regimen covers HBV)
• DAAs for HCV can be used safely in HIV-positive patients (check drug–drug interactions)

4. Immunosuppressed Patients / Biologic Therapy

• HBV reactivation risk with rituximab, corticosteroids, TNF-α inhibitors, chemotherapy
• Prophylactic entecavir or tenofovir before immunosuppression in all HBsAg+ patients
• Occult HBV (HBsAg–/anti-HBc+) also at risk — monitor HBV DNA

"Special populations deserve dedicated attention. HBV in pregnancy is the world's single most important perpetuator of chronic HBV infection. Combination of neonatal vaccine plus HBIG at birth reduces vertical transmission by 85 to 95%. For high viral load mothers — above 200,000 IU/mL — adding tenofovir in the third trimester reduces it further. On the opposite end, HEV in pregnancy is a true obstetric emergency with 20% mortality in the third trimester."

---

SLIDE 22 — PREVENTION SUMMARY

"Vaccination is the cornerstone of prevention for HAV, HBV — and by extension HDV. The HBV vaccine program, introduced universally in many countries, is one of the world's most effective anti-cancer vaccines — it prevents HCC. There is currently no vaccine or post-exposure prophylaxis for HCV, making harm reduction and universal screening the primary public health strategies."

---

SLIDE 23 — A CLINICAL APPROACH: ALGORITHM

1. History: Exposures (travel, shellfish, IV drugs, sexual contacts, tattoos, blood transfusion, medications), alcohol, family history, HIV status, pregnancy
2. Physical exam: Jaundice, hepatomegaly, splenomegaly, spider nevi, asterixis (encephalopathy)
3. Initial labs:
   • LFTs: ALT, AST, ALP, GGT, total + direct bilirubin, albumin
   • PT/INR (synthetic function)
   • CBC, BMP
4. Viral serology panel (simultaneously):
   • Anti-HAV IgM
   • HBsAg, Anti-HBc IgM, HBV DNA
   • Anti-HCV → if positive, HCV RNA + genotype
   • Anti-HDV (if HBsAg positive)
   • Anti-HEV IgM (if endemic exposure or pregnancy)
5. Assess severity:
   • INR >1.5 + encephalopathy → Acute Liver Failure protocol
   • Consider liver biopsy if uncertain diagnosis
6. Management: Targeted per etiology + supportive care

"In clinical practice, you'll receive a patient with 'elevated liver enzymes' — your diagnostic algorithm must be systematic. Run all the serologies simultaneously rather than sequentially to avoid delay. The PT/INR is your most critical acute prognostic tool. An INR above 1.5 with any mental status change means you need to immediately consider acute liver failure management and transplant evaluation."

---

SLIDE 24 — KEY TAKEAWAYS & SUMMARY

1. HAV & HEV: Fecal-oral, self-limited (except HEV in pregnancy), no chronic infection in immunocompetent
2. HBV: DNA virus, 300M chronic carriers, perinatal transmission causes 90% chronicity; treat with tenofovir or entecavir; vaccine prevents both HBV and HDV
3. HCV: RNA virus, 80–90% chronicity, 95%+ cure with 8–12 weeks of DAAs (sofosbuvir-based); no vaccine
4. HDV: Defective virus requiring HBV; superinfection carries worst prognosis; HBV vaccination is ultimate prevention
5. HEV: Particularly dangerous in pregnancy (20% FHF mortality); chronic in immunosuppressed
6. Complications: Fulminant failure (transplant emergency), cirrhosis, HCC — surveillance with US ± AFP q6 months
7. Screen everyone: CDC recommends universal HCV screening (age 18–79) and HBsAg testing in high-risk groups

"To summarize: viral hepatitis remains one of the most clinically impactful infectious diseases globally. The field has been transformed — HCV is now curable, HBV can be suppressed indefinitely, and our serological tools allow precise diagnosis. Your role as internists is to screen proactively, diagnose accurately, initiate timely antiviral therapy, monitor for complications, and prevent transmission. Thank you."

---

SLIDE 25 — REFERENCES

• Robbins & Kumar Basic Pathology (10th Ed.) — Viral Hepatitis, Chapter 14
• Sleisenger & Fordtran's Gastrointestinal and Liver Disease — Chapters 73, 82
• Yamada's Textbook of Gastroenterology (7th Ed.) — Table 87.5 (CHB Guidelines)
• Katzung's Basic and Clinical Pharmacology (16th Ed.) — Direct-Acting Antivirals for HCV
• Goldman-Cecil Medicine — Antivirals for Hepatitis B
• EASL Clinical Practice Guidelines: HBV (2017)
• AASLD Guidance on Chronic Hepatitis B (2018)
• WHO Guidelines on Hepatitis B & C (2015/2018)

---

PRESENTATION TIPS

• Total time: ~45–60 minutes (teaching session) or 20–25 minutes (grand rounds)
• Audience engagement: Use the serology table (Slide 10) as a case-based quiz
• Case scenarios to consider inserting:
  • 28-year-old IV drug user: anti-HCV+, HCV RNA+, Gt 1a → initiating DAA therapy
  • Pregnant woman from India at 32 weeks with jaundice + coagulopathy → Acute HEV
  • HBsAg+ patient starting rituximab for lymphoma → prophylactic entecavir
  • 45-year-old with HBsAg+, ALT 120, HBV DNA 450,000 IU/mL, HBeAg+ → treat with TDF or ETV